Showing results (21-30 of 58) with videos related to
Sort By:
Pageof 6
European Journal of Pharmacology|September 23, 1987
Inhibition of plasma cholinesterase prevents the dopamine DA-1 receptor mediated renal vasodilation produced by ibopamineA J Nichols, R J Shebuski, R R RuffoloPharmacology|January 1, 1988
Comparison of the renal and pulmonary hemodynamic effects of fenoldopam, dobutamine, dopamine and norepinephrine in the anesthetized dogR J Shebuski, J M Smith, R R RuffoloFundamental & Clinical Pharmacology|January 1, 1989
Effect of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on tPA-induced thrombolysis in a rabbit model of femoral arterial thrombosisT Fujita, S Hasan, B L Storer, et al.Thrombosis Research|May 15, 1987
Tissue-type plasminogen activator and streptokinase induce platelet hyperaggregability in the rabbitE H Ohlstein, B Storer, T Fujita, et al.Journal of Cardiovascular Pharmacology|January 1, 1993
The snake venom peptide sarafotoxin S6b inhibits repetitive platelet thrombus formation in the stenosed canine coronary arteryR J Leadley, P Lee, L A Erickson, et al.The Journal of Pharmacology and Experimental Therapeutics|April 1, 1987
Comparison of the alpha adrenoceptor activity of dopamine, ibopamine and epinine in the pulmonary circulation of the dogR J Shebuski, T Fujita, J M Smith, et al.The Journal of Pharmacology and Experimental Therapeutics|January 1, 1989
Localization and characterization of alpha-2 adrenoceptors in the isolated canine pulmonary veinE H Ohlstein, S Horohonich, R J Shebuski, et al.Federation Proceedings|May 15, 1981
Analysis of the biological activity of azoprostanoids in human plateletsR R Gorman, R J Shebuski, J W Aiken, et al.Pharmacology|January 1, 1991
Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosisM A Holahan, M J Mellott, V M Garsky, et al.Prostaglandins|August 1, 1980
6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agentO V Miller, J W Aiken, R J Shebuski, et al.Pageof 6